Virologic Research

We collect virological samples for a broad variety of pathogens and determine virological and genomic parameters. We are a German and European partner in assembling large databases regarding viral resistance and investigating clinically relevant questions on the basis of such data.

Our research is aimed at collecting virologically and clinically relevant data on viral resistance and performing analyses based on the resulting data collections. For this purpose we have cofounded and are partnering in several national and international consortia.

Arevir is a German consortium founded around the turn of the millennium. The consortium comprises clinicians, virologists and bioinformaticians for the purpose of data collection and analysis. The consortium has brought forth the geno2pheno Server which affords bioinformatical drugs resistance analysis of several viruses based on viral genotype. This server is used world-wide in research and clinic. The consortium is researching towards continual extension and refinement of resistance analyses for a growing number of viral resistance phenotypes and laboratory assay for generating diagnostic data.

Euresist is a European consortium found in 2005 which performs data collection and analysis at the European level. With over 200,000 records of drug therapy assignments and their follow-up, the Euresist database is one of the largest such scientific database world-wide. Aside from the data, which are available upon reasonable request, Euresist offers analysis tools for resistance prediction, phylogeny and geographic distribution.

Respvir is a German-Austrian-Swiss consortium which collects data on seasonal incidence of viral infection of the respiratory tract. The data collected by the network are instrumental for analyzing and predicting seasonal outbreaks. Since 2020, data collection has included SARS-Cov-2 and interesting correlations between seasonal patterns of this and other respiratory viruses have been detected that could serve to better understand the effect of noninvasive interventions for protection against SARS-Cov-2.